BEKINDA® (formerly RHB-102) is a proprietary, oral, extended-release (24 hours), once-daily pill formulation of the antiemetic drug ondansetron, targeting multiple gastrointestinal indications.
Ondansetron is a 5-HT3 (serotonin) receptor antagonist which is marketed under various trade names including GSK’s Zofran®. 5-HT3 receptor antagonists are considered the most effective and significant class of drugs in prevention of nausea and vomiting.
BEKINDA® is currently the only once-daily oral formulation of ondansetron, and is likely to be the first to reach the U.S. and European market.
BEKINDA® was licensed from SCOLR Pharma, Inc. [Amex: DDD] in May 2010. RedHill secured the direct rights to the original patents from Temple University, following SCOLR’s announcement that the they had ceased their business operations.
BEKINDA® is being developed for several indications :
- Gastroenteritis and Gastritis: a Phase III clinical study in ongoing in the U.S.
- IBS-D: a Phase II clinical study is ongoing in the U.S. for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D)
- Oncology Support: European marketing application for prevention of chemotherapy and radiotherapy-induced nausea and vomiting submitted and withdrawn. Under discussions with EU Member States